FDA Approval of Obesity Drugs: a Difference in Risk-benefit Perceptions

Overview

Journal JAMA

Publisher American Medical Association

Specialty General Medicine

Date 2012 Sep 20

PMID 22990266

Citations 5

Authors

Elaine H Morrato

David B Allison

Affiliations

Soon will be listed here.

Citing Articles

Anti-Obesity Agents and the US Food and Drug Administration.

Casey M, Mechanick J Curr Obes Rep. 2015; 3(3):361-7.

PMID: 26626768 DOI: 10.1007/s13679-014-0115-x.

Successful Medical Weight Loss in a Community Setting.

Carney D, Schultz S, Lim J, Walters W J Obes Weight Loss Ther. 2015; 5(1).

PMID: 26613067 PMC: 4657754. DOI: 10.4172/2165-7904.1000248.

The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation.

Chawla A, Carls G, Deng E, Tuttle E Pharmacoeconomics. 2015; 33(7):749-63.

PMID: 26054325 DOI: 10.1007/s40273-015-0300-0.

The use of expensive technologies instead of simple, sound and effective lifestyle interventions: a perpetual delusion.

Carlos S, de Irala J, Hanley M, Martinez-Gonzalez M J Epidemiol Community Health. 2014; 68(9):897-904.

PMID: 24962820 PMC: 4145453. DOI: 10.1136/jech-2014-203884.

GUCY2C: at the intersection of obesity and cancer.

Kim G, Lin J, Waldman S Trends Endocrinol Metab. 2013; 24(4):165-73.

PMID: 23375388 PMC: 3617062. DOI: 10.1016/j.tem.2013.01.001.

References

Topol E . Failing the public health--rofecoxib, Merck, and the FDA. N Engl J Med. 2004; 351(17):1707-9. DOI: 10.1056/NEJMp048286. View

Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe P, Egger M . Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004; 364(9450):2021-9. DOI: 10.1016/S0140-6736(04)17514-4. View

. FDA approves Belviq to treat some overweight or obese adults. Home Healthc Nurse. 2012; 30(8):443-4. View

Slovic P . Perception of risk. Science. 1987; 236(4799):280-5. DOI: 10.1126/science.3563507. View